Manifestaciones mucocutáneas en pacientes hospitalizados por COVID 19 en un hospital de alta complejidad / Mucocutaneous manifestations in patients hospitalized with covid-19 in a high complexity hospital

Resumen Introducción: el SARS-CoV-2 es un virus ARN de cadena simple que compromete diferentes órganos, incluyendo la piel. Los pacientes que cursan con este virus pueden presentar diferentes manifestaciones mucocutáneas. Objetivo: determinar la prevalencia de las lesiones mucocutáneas en pacientes hospitalizados por infección SARS-CoV-2/COVID 19 en el Hospital San Vicente Fundación Rionegro entre abril y junio del 2021. Materiales y métodos: estudio descriptivo transversal en pacientes hospitalizados con diagnóstico de infección por COVID-19 confirmado por pruebas serológicas y con lesiones mucocutáneas. Resultados: de 600 pacientes hospitalizados por COVID-19, 16 presentaron lesiones mucocutáneas para una prevalencia del 2,6%, y entre estos, 13 requirieron manejo en unidad de cuidados intensivos por síndrome de dificultad respiratoria aguda severa o enfermedad severa (81,25%) asociado a marcadores de mal pronóstico elevados. Los más elevados fueron la PCR, LDH o la presencia de linfopenia. Las lesiones vasculares fueron las más frecuentes (42,9%), que se manifestaron como púrpuras, vasculitis, livedo racemosa, perniosis y pseudoperniosis. Las erupciones o exantemas fueron de tipo maculopapulares (28,6%), eritematosas (19%) y urticariales (9,5%); además de úlceras en cavidad oral (8,8%) y vesículas (2,9%). El 75% de estos pacientes presentaron lesiones cutáneas en la fase activa de la enfermedad y el 25% en la fase resolutiva. Las morbilidades más frecuentes fueron hipertensión arterial (30%) y diabetes (20%). Seis pacientes fallecieron (37,5%). Conclusiones: las manifestaciones mucocutáneas asociadas al COVID-19, especialmente las de tipo vascular como las púrpuras, vasculitis y livedo racemosa, se asocian a formas graves de la enfermedad, especialmente en pacientes con ventilación mecánica asistida con un alto índice de mortalidad.

Abstract Introduction: SARS-CoV-2 is a single-stranded RNA virus that affects different organs, including the skin. Patients with this virus can present different mucocutaneous manifestations. Objective: to determine the prevalence of skin lesions in patients hospitalized for SARS-CoV-2 / COVID 19 infection at the Hospital San Vicente Fundación Rionegro between April and June 2021. Materials and methods: descriptive cross-sectional study in hospitalized patients with a diagnosis of infection by COVID-19 confirmed by serological tests and with mucocutaneous lesions. Results: of 600 patients hospitalized for COVID-19, 16 presented mucocutaneous lesions for a prevalence of 2,6 %, and among these, 13 required management in the intensive care unit due to severe acute respiratory distress syndrome or severe illness (81,25%) associated with elevated markers of poor prognosis. The most increased were PCR, LDH and/or lymphopenia. Vascular lesions were the most frequent (42,9%), manifested as purples, vasculitis, livedo racemosa, perniosis and pseudoperniosis. The eruptions or rashes were maculopapular (28.6%), erythematous (19%) and urticarial (9,5%), and ulcers in the oral cavity (8,8%) and vesicles (2,9%). 75% of these patients had skin lesions in the active phase of the disease and 25% in the resolution phase. The most frequent morbidity was arterial hypertension (30%) and diabetes (20%). six patients (37,5%) died. Conclusions: the mucocutaneous manifestations associated with COVID-19, especially those of a vascular type such as purples, vasculitis and livedo racemosa, are associated with severe forms of the disease, especially in patients with assisted mechanical ventilation with a high mortality rate.

Out-of-pocket costs for patients with psoriasis in an outpatient dermatology referral service

Abstract Background: Psoriasis is a chronic disease that derives great costs to the health care system. In Colombia, due to deficiencies in this system, patients are more likely to incur in out-of-pocket expenses; money that has never been quantified in this country. Objectives: To quantify out-of-pocket expenses and to analyze their relation to patients' clinical and labor characteristics in a cohort of psoriatic patients. Methods: A single-center, cross-sectional study was performed, evaluating psoriasis patients. Results: A total of 100 psoriasis patients were analyzed. We identified that patients with higher dermatology life quality index and in phototherapy treatment were the ones that had higher out-of-pocket costs (p = 0.006 and 0.005, respectively). We found no correlation between out-of-pocket costs and occupational status, psoriasis area severity index or other types of treatment. The largest amount of money was used to buy medications and bus transportation with a maximum up to 440.50 and 528.60 USD, respectively. Among the 100 participants the total expense was 11131.90 USD in a 6-month period. Study limitations: Lack of measurement of the labor productivity and labor absenteeism secondary to sick leave. Conclusion: Out-of-pocket costs are similar with what was shown in previous studies. We found statistically significant differences for the DLQI in comparison with out-of-pocket expenses, regardless of the PASI level. Phototherapy treatment also had statistically significant differences in relationship with out-of-pocket expenses, when compared to other treatments, because it requires higher expenses in transportation, copayments, and alimentation during appointment assistance.

Minociclina en el tratamiento de la dermatitis periorificial granulomatosa en un niño de raza blanca, sin respuesta a otras tetraciclinas / Minocycline in the treatment of periorificial granulomatous dermatitis in a white child without response to other tetracyclines

La dermatitis periorificial granulomatosa es una entidad poco frecuente que fue inicialmente reportada en niños de raza negra, recibiendo el nombre de erupción facial de la niñez afroamericana. Posteriormente se encontró que dicha enfermedad puede presentarse en personas de todas las razas. El uso crónico de esteroides tópicos es el principal factor desencadenante, por lo que la suspensión de estos es la piedra angular en el tratamiento de esta entidad. Reportamos el caso de un niño de 14 años, con un cuadro de ocho meses de evolución de pápulas eritematosas bien definidas, localizadas en párpados inferiores y surcos nasolabiales con descamacion y eritema circundantes. Fue tratado con deflazacort, medrol, esteroides tópicos de alta potencia, dapsona, e isotretinoína oral, con poca mejoría. La biopsia de piel reportó granulomas no caseificantes compuestos por macrofagos epitelioides y un infiltrado inflamatorio linfocitario adyacente, haciéndose el diagnóstico de una dermatitis periorificial granulomatosa. El paciente fue tratado con minociclina oral y tacrolimus tópico, con desaparición de casi todas las lesiones después de un mes y medio de tratamiento.

Periorificial granulomatous dermatitis is a rare entity that was first reported in black children. Because of this, it was called facial afro-caribbean childhood eruption. However, in later publications it was found that this disease can occur in people of all races. Chronic use of topical steroids is the major exacerbating factor and the suspension of these is the cornerstone of treatment. We report the case of a 14 year-old boy with 8 months of well-defined erythematous papules located on his lower eyelids and nasolabial folds with surrounding erythema and desquamation. He was treated with deflazacort, medrol, high potency topical steroids, dapsone, and oral isotretinoin, with little improvement. Skin biopsy reported noncaseating granulomas composed of epithelioid macrophages and lymphocytic inflammatory infiltrate. The diagnosis of periorificial granulomatous dermatitis was made based on clinical history, physical examination and histology. Management was initiated with oral minocycline and topical tacrolimus, with almost complete disappearance of lesions after a month and a half of treatment.

Síndrome poliglandular autoinmune asociado a vitiligo / Vitiligo-asociated autoimmune polyglandular syndrome

El síndrome poliglandular autoinmune es un desorden inmunológico que afecta diferentes glándulas endocrinas y que se asocia frecuentemente a enfermedades cutáneas de origen autoinmune como el vitiligo. Actualmente se clasifica en tres grupos de acuerdo a las glándulas comprometidas. El síndrome poliglandular autoinmune tipo IIIB es el más comúnmente reportado y se caracteriza por enfermedad tiroidea autoinmune con gastritis autoinmune. Aunque hay asociación con alopecia areata, es el vitiligo la enfermedad cutánea que más se asocia con este síndrome. Se presenta el caso de una paciente de 50 años con síndrome poliglandular autoinmune tipo IIIB, quien presentó inicialmente una tiroiditis autoinmune, posteriormente fue diagnosticada con anemia perniciosa secundaria a deficiencia de vitamina B12 y finalmente un vitiligo generalizado, resistente a múltiples tratamientos, a pesar del control de sus endocrinopatías.

Autoimmune poliglandular syndrome is an immune disorder, that affects different endocrine glands and that is frequently associated with cutaneous disorders of autoinmune etiology like vitiligo. It is currently classified in three groups depending on the compromised gland. Type IIIB autoimmune polyglandular syndrome is the most frequently reported and is characterized by autoimmune thyroid disease with autoimmune gastritis. Although, it is also associated wih alopecia areata, vitiligo is the most frequently cutaneous disease reported in this syndrome. We report a 50 year old woman with a type IIIB autoimmune poliglandular síndrome who had an autoimmune thyroid disease with hyperthyroidism 25 years before, later she was diagnosed with pernicious anemia secondary to vitamin B12 deficiency and finally presented a generalized vitiligo, resistant to multiple treatments des-pite good control of her autoimmune illnesses.